Drawing for NYJANBA

USPTO serial 79339429

NYJANBA

Reviewed by CopyMark Law Group

Reg. 6882155Status 404
Filing date
Status date
Registration date
Oct 25, 2022
Examiner
KEAM, ALEX S
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with NYJANBA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 BENSON DRRALEIGH, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaSECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 12, 2025DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Jun 12, 2025DETHDEATH OF INTERNATIONAL REGISTRATION—
Mar 14, 2023FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Feb 18, 2023FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 17, 2023FIMPFINAL DISPOSITION PROCESSED—
Jan 25, 2023FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 25, 2022NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 25, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 9, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 9, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 8, 2022RFNTREFUSAL PROCESSED BY IB—
Jul 20, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 11, 2022RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jul 11, 2022RFRRREFUSAL PROCESSED BY MPU—
Jul 7, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 7, 2022XAECEXAMINER'S AMENDMENT ENTERED—
Jul 7, 2022GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 7, 2022GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 7, 2022CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 7, 2022RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 6, 2022GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jul 6, 2022GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jul 6, 2022CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jul 5, 2022DOCKASSIGNED TO EXAMINER—
Jun 20, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jun 20, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 20, 2022ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jun 20, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 20, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 20, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 14, 2022MAFRAPPLICATION FILING RECEIPT MAILED—
May 10, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 9, 2022LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Apr 28, 2022SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance